Evaluation Of Naturally Occurring Resistance To Direct Acting Antiviral Drugs (DAAs) In Individuals With Acute Hepatitis C Infection
Funder
National Health and Medical Research Council
Funding Amount
$333,778.00
Summary
Hepatitis C therapy in the future is likely to involve the use of Directly Acting Antivirals, which offer a better chance of treatment success and shorter treatment courses. The downside to these new agents is the possible development of drug resistance. Studies suggest that drug resistant strains may already exist in some individuals prior to treatment. This study plans to use sensitive methods to examine how common drug resistant strains are in untreated individuals with acute hepatitis C.
Recently Acquired Hepatitis C Infection: Insights From Virological, Therapeutic And Epidemiological Studies
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
Every year around 10,000 new cases of hepatitis C (HCV) infection occur within Australia, most of which are undiagnosed. Reasons for this include a lack of public awareness about the benefits of treatment at this stage. As new antiviral agents become available it is likely that therapy for recent HCV will become even easier and more successful. The aim of this research is to explore HCV transmission patterns, treatment strategies and long term health outcomes in people with recent HCV.